Medicine
Delstrigo 100 mg/300 mg/300 mg tablet
Delstrigo 100 mg/300 mg/300 mg tablet is a prescription medicine containing Doravirine, Lamivudine and Tenofovir disoproxil for oral use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store DELSTRIGO at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C…
Key facts
- Active ingredient (INN)
- Doravirine, Lamivudine and Tenofovir disoproxil
- Brand
- Delstrigo
- Strength
- 100 mg/300 mg/300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Store DELSTRIGO at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store DELSTRIGO in the original bottle. Keep the bottle tightly closed to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR Efavirenz/lamivudine/tenofovir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 July 2018
- Identifiers
- RxCUI 2055813, 2055815DailyMed set ID cd1e9f84-607a-46d3-b01e-2736018d67b6NDC 0006-5007Application NDA210807
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 0006-5007-01 | Merck Sharp & Dohme | 20 July 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Doravirine, Lamivudine and Tenofovir disoproxil is a fixed-dose combination of a hepatitis B virus nucleoside analog reverse transcriptase inhibitor, a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor and a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Doravirine, Lamivudine and Tenofovir disoproxil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Doravirine, Lamivudine and Tenofovir disoproxilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- DELSTRIGO prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Delstrigo: European public assessment report (EPAR) · European Medicines Agency
Need Delstrigo 100 mg/300 mg/300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.